Berzosertib + Irinotecan for Gastric Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications, but it advises avoiding certain drugs that interact with the trial medications. You should discuss your current medications with the study team to ensure there are no interactions.
What data supports the effectiveness of the drug combination Berzosertib and Irinotecan for gastric cancer?
Research shows that Irinotecan, when combined with other drugs like S-1 or cisplatin, has shown some effectiveness in treating advanced gastric cancer, with response rates ranging from 16.1% to 23.3% and a high tumor control rate. This suggests potential for Irinotecan in combination therapies, although specific data on Berzosertib is not provided.12345
Is the combination of Berzosertib and Irinotecan safe for humans?
Irinotecan has been studied in various cancers, including gastric cancer, and common side effects include low white blood cell counts, diarrhea, and nausea, which are generally reversible. While specific safety data for the combination of Berzosertib and Irinotecan is not provided, Irinotecan alone has shown manageable side effects in clinical trials.12567
What makes the drug combination of Berzosertib and Irinotecan unique for treating gastric cancer?
The combination of Berzosertib and Irinotecan for gastric cancer is unique because Berzosertib is a novel drug that targets the ATR (ataxia telangiectasia and Rad3-related) pathway, potentially enhancing the effectiveness of Irinotecan, which is already used in various combinations for gastric cancer. This approach may offer a new mechanism of action compared to existing treatments.13489
What is the purpose of this trial?
This trial tests a combination of berzosertib and irinotecan in patients with advanced gastric or gastroesophageal junction cancer. Berzosertib blocks enzymes needed for cancer growth, and irinotecan kills or stops the spread of cancer cells. Irinotecan has been used in various combinations for treating advanced gastric and gastroesophageal cancers, showing some efficacy but not proving superior to other treatments. The goal is to find a more effective treatment for these difficult-to-treat cancers.
Research Team
Jordan D Berlin
Principal Investigator
Yale University Cancer Center LAO
Eligibility Criteria
This trial is for adults over 18 with progressive, metastatic, or unresectable gastric or gastroesophageal junction cancer that has a TP53 mutation. Participants must have tried at least two systemic therapies and meet certain health criteria (like blood cell counts). Women of childbearing age and men with partners of childbearing age must use contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive irinotecan IV over 90 minutes and berzosertib IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion, with follow-up every 2 months for up to 1 year.
Treatment Details
Interventions
- Berzosertib
- Irinotecan
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor